Haff disease medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 16: | Line 16: | ||
=====Hyperkalemia<ref name="pmid28846335">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=28846335 | doi= | pmc= | url= }} </ref>===== | =====Hyperkalemia<ref name="pmid28846335">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=28846335 | doi= | pmc= | url= }} </ref>===== | ||
*'''Potassium levels less than 6 mEq/L without EKG changes:''' managed with potassium binders | *'''Potassium levels less than 6 mEq/L without EKG changes:''' managed with potassium binders and use of bicarbonate in fluids. | ||
*'''Potassium levels 6 mEq/L or above with or without EKG changes:''' ampule of D50 followed by zero units of regular insulin | *'''Potassium levels 6 mEq/L or above, with or without EKG changes:''' ampule of D50 followed by zero units of regular insulin and IV sodium bicarbonate. | ||
=====Hypocalcemia<ref name="pmid28846335">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=28846335 | doi= | pmc= | url= }} </ref>===== | =====Hypocalcemia<ref name="pmid28846335">{{cite journal| author=| title=StatPearls | journal= | year= 2022 | volume= | issue= | pages= | pmid=28846335 | doi= | pmc= | url= }} </ref>===== | ||
| Line 26: | Line 26: | ||
*'''[[Disseminated intravascular coagulation]]:''' should be managed with fresh frozen plasma, cryoprecipitate, and platelet transfusion. | *'''[[Disseminated intravascular coagulation]]:''' should be managed with fresh frozen plasma, cryoprecipitate, and platelet transfusion. | ||
*'''[[Compartment syndrome]]:''' emergent orthopedic consultation is required<br /> | *'''[[Compartment syndrome]]:''' emergent orthopedic consultation is required.<br /> | ||
==References== | ==References== | ||
| Line 35: | Line 35: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Syndromes]] | [[Category:Syndromes]] | ||
[[Category: | [[Category:Up to Date]] | ||
Latest revision as of 19:38, 27 April 2022
|
Haff disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Haff disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Haff disease medical therapy |
|
Risk calculators and risk factors for Haff disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
The medical therapy of Haff disease consists of managing rhabdomyolysis by aggressive fluid hydration, managing electrolyte abnormalities (hyperkalemia and hypocalcemia), and other supportive care.
Medical therapy
Management of Rhabdomyolysis
The goal of rhabdomyolysis is adequate fluid hydration with normal isotonic saline to prevent acute kidney injury. Urine output of 200 to 300 mL/h should be maintained with daily serial monitoring of CPK level to document a downward trend. In case of fluid overload from aggressive fluid resuscitation, loop diuretics may be considered.[1] In severe cases with CPK level > 30,000 IU/L, alkalization of the urine with bicarbonate can be considered.[1][2]
Management of Electrolytes Abnormalities
Rhabdomyolysis is associated with hyperkalemia and hypocalcemia.[1]
Hyperkalemia[1]
- Potassium levels less than 6 mEq/L without EKG changes: managed with potassium binders and use of bicarbonate in fluids.
- Potassium levels 6 mEq/L or above, with or without EKG changes: ampule of D50 followed by zero units of regular insulin and IV sodium bicarbonate.
Hypocalcemia[1]
- Symptomatic hypocalcemia: should be treated with IV calcium gluconate.
Other Supportive Care[1]
- Disseminated intravascular coagulation: should be managed with fresh frozen plasma, cryoprecipitate, and platelet transfusion.
- Compartment syndrome: emergent orthopedic consultation is required.